Hypoxia as a therapy for mitochondrial disease.
| Authors | |
| Keywords | |
| Abstract | Defects in the mitochondrial respiratory chain (RC) underlie a spectrum of human conditions, ranging from devastating inborn errors of metabolism to aging. We performed a genome-wide Cas9-mediated screen to identify factors that are protective during RC inhibition. Our results highlight the hypoxia response, an endogenous program evolved to adapt to limited oxygen availability. Genetic or small-molecule activation of the hypoxia response is protective against mitochondrial toxicity in cultured cells and zebrafish models. Chronic hypoxia leads to a marked improvement in survival, body weight, body temperature, behavior, neuropathology, and disease biomarkers in a genetic mouse model of Leigh syndrome, the most common pediatric manifestation of mitochondrial disease. Further preclinical studies are required to assess whether hypoxic exposure can be developed into a safe and effective treatment for human diseases associated with mitochondrial dysfunction. |
| Year of Publication | 2016
|
| Journal | Science
|
| Volume | 352
|
| Issue | 6281
|
| Pages | 54-61
|
| Date Published | 2016 Apr 01
|
| ISSN | 1095-9203
|
| URL | |
| DOI | 10.1126/science.aad9642
|
| PubMed ID | 26917594
|
| PubMed Central ID | PMC4860742
|
| Links | |
| Grant list | R01DK090311 / DK / NIDDK NIH HHS / United States
R24 OD017870 / OD / NIH HHS / United States
R01 MH110049 / MH / NIMH NIH HHS / United States
K99 HG008171 / HG / NHGRI NIH HHS / United States
5DP1-MH100706 / DP / NCCDPHP CDC HHS / United States
K99-HG008171 / HG / NHGRI NIH HHS / United States
1R01-MH110049 / MH / NIMH NIH HHS / United States
DP1 MH100706 / MH / NIMH NIH HHS / United States
Howard Hughes Medical Institute / United States
R01 DK097768 / DK / NIDDK NIH HHS / United States
5R01DK097768-03 / DK / NIDDK NIH HHS / United States
R01 DK090311 / DK / NIDDK NIH HHS / United States
R24OD017870 / OD / NIH HHS / United States
|